Antidepressant-like effect of Valeriana glechomifolia Meyer (Valerianaceae) in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 36, Issue 1, 2012, Pages 101-109

  Müller, Liz G ^a   Salles, Luisa A ^a   Stein, Ana C ^a   Betti, Andresa H ^a   Sakamoto, Satchie ^a   Cassel, Eduardo ^b   Vargas, Rubem Figueiró ^b   von Poser, Gilsane L ^a   Rates, Stela M K ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Antidepressant; Forced swimming test; Tail suspension test; Valepotriates; Valeriana glechomifolia

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMFEBUTAMONE; CARBON DIOXIDE; DESIPRAMINE; FENCLONINE METHYL ESTER; FLUOXETINE; IMIPRAMINE; PLANT EXTRACT; PRAZOSIN; SULPIRIDE; UNCLASSIFIED DRUG; VALERIANA GLECHOMIFOLIA EXTRACT; YOHIMBINE;

ADRENERGIC TRANSMISSION; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG ANTAGONISM; DRUG STRUCTURE; IMMOBILIZATION; LOCOMOTION; MALE; MOTOR COORDINATION; MOUSE; NONHUMAN; SEROTONINERGIC TRANSMISSION; VALERIANA GLECHOMIFOLIA; VALERIANACEAE;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HINDLIMB SUSPENSION; MALE; MICE; MOTOR ACTIVITY; PLANT EXTRACTS; SWIMMING; VALERIAN;

EID: 82555190931     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.08.015     Document Type: Article

References (58)

1. Backlund A., Moritz T. Phylogenetic implications of an expanded valepotriate distribution in the Valerianaceae. Biochem Syst Ecol 1998, 26:309-335.
2. Bai F., Li X., Clay M., Lindstrom T., Skolnick P. Intra and interstrain differences in models of "behavioral despair". Pharmacol Biochem Behav 2001, 70:187-192.
3. Baumann P. Pharmacotherapy of depression: recent developments. Rev Med Suisse 2007, 3(125):2079-2080.
4. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-141.
5. Bettero G.M., Salles L., Rosário R.M.F., von Poser G.L., Rates S.M.K., Noêl F., et al. In vitro effect of valepotriates isolated from Valeriana glechomifolia on rat P-type ATPases. Planta Med 2011, 77:1702-1706.
6. Bhattacharyya D., Jana U., Debnath P.K., Sur T.K. Initial exploratory observational pharmacology of Valeriana wallichii on stress management: a clinical report. Nepal Med Coll J 2007, 9:36-39.
7. Bounthanh C., Richter L., Beck J.P., Haag-Berruier M., Anton R. The action of valepotriates on the synthesis of DNA and proteins of cultured hepatoma cells. Planta Med 1983, 49:138-142.
8. Bourin M., Chenu F., Ripoll N., David D.J.P. A proposal of decision tree to screen putative antidepressants using forced swim and tail suspension tests. Behav Brain Res 2005, 164:266-269.
9. Brunello N., Mendlewikz J., Kasper S., Leonard B., Montgomery S., Craig Nelson J., et al. The role of noradrenaline and noradrenaline reuptake inhibitors in depression. Eur Neuropsychopharmacol 2002, 12:461-475.
10. Cassel E., Vargas R.M.F., Brun G.W., Almeida D.E., Cogoi L., Ferraro G., et al. Supercritical fluid extraction of alkaloids from Ilex paraguariensis St. Hill. J Food Eng 2010, 100:656-661.
11. A receptor in rat brain. Arzneimittelforschung 1995, 45:753-755.
12. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005, 29:571-625.
13. D'Aquila P.S., Collu M., Gessa G.L., Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000, 405:365-373.
14. Dell'Osso B., Palazzo C.M., Oldani L., Altamura A.C. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects. CNS Neurosci Ther 2010, 10.1111/j.1755-5949.2010.00217.x.
15. Duarte F.S., Lach G., Martins P.R.C., Romeiro G.A., Lima T.C.M. Evidence for the involvement of the monoaminergic system in the antidepressant-like action of two 4-amine derivatives of 10, 11-dihydro-5H-dibenzo [a, d] cycloheptane in mice evaluated in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:368-374.
16. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007, 64:327-337.
17. + ATPase hypothesis for bipolar illness. Biol Psychiatry 1995, 37:235-244.
18. Estrada-Soto S., Rivera-Leyva J., Ramírez-Espinosa J.J., Castillo-España P., Aguirre-Crespo F., Hernández-Abreu O. Vasorelaxant effect of Valeriana edulis ssp. procera (Valerianaceae) and its mode of action as calcium channel blocker. J Pharm Pharmacol 2010, 62(9):1167-1174.
19. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry 2000, 61(suppl 1):26-32.
20. Gherson A.A., Vishne T., Grunhaus L. Dopamine D2-like receptors and the antidepressant response. Biol Psychiatry 2007, 61:145-153.
21. Greenberg P.E., Kessler R.C., Birnbaum H.G., Leong S.A., Lowe S.W., Berglund P.A., et al. The economic burden of depression in the United States: how did it change between 1990 and 2000?. J Clin Psychiatry 2003, 64:1465-1475.
22. Hattesohl M., Feistel B., Sievers H., Lehnfeld R., Hegger M., Winterhoff H. Extracts of Valeriana officinalis L. s.l. show anxiolitic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine 2008, 15:2-15.
23. Hazelholff B., Malingré T.M., Meijer D.K. Antispasmodic effects of valeriana compounds: an in vivo and in vitro study on the guinea-pig ileum. Arch Int Pharmacodyn Ther 1982, 257:274-287.
24. Holzmann I, Filho VC, Mora TC, Cáceres A, Martínez JV, Cruz SM, et al. Evaluation of behavioral and pharmacological effects of hydroalcoholic extract of Valeriana prionophylla Standl. from Guatemala. eCAM in press. doi:. doi:10.1155/2011/312320.
25. 3 receptors in the antidepressant-like effect caused by oral administration of bis selenide in mice. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:294-302.
26. Kwon S., Lee B., Kim M., Lee H., Park H.J., Hahm D.H. Antidepressant-like effect of the methanolic extract from Bupleurum falcatum in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:265-270.
27. Lacher S.K., Mayer R., Sichardt K., Nieber K., Müller C.E. Interaction of valerian extracts of different polarity with adenosine receptors: identification of isovaltrate as an inverse agonist at A1 receptors. Biochem Pharmacol 2007, 73:248-258.
28. Lam R.W., Wan D.D., Cohen N.L., Kennedy S.H. Combining antidepressants for treatment resistant depression: a review. J Clin Psychiatry 2002, 63:685-693.
29. Lambert G., Johansson M., Agren H., Friberg P. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry 2000, 57:787-793.
30. Lin S., Shen Y.-H., Li H.-L., Yang X.-W., Chen T., Lu L.-H., et al. Acylated iridoids with cytotoxicity from Valeriana jatamansi. J Nat Prod 2009, 72:650-655.
31. Marder M., Viola H., Wasowski C., Fernández S., Medina J.H., Paladini A.C. 6-Methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS. Pharmacol Biochem Behav 2003, 75:537-545.
32. Maurmann N., Reolon G.K., Rech S.B., Fett-Neto A.G., Roesler R. A valepotriate fraction of Valeriana glechomifolia shows sedative and anxiolytic properties and impairs recognition but not aversive memory in mice. eCAM 2009, 10.1093/ecam/nep232.
33. Mennini T., Bernasconi P., Bombardelli E., Morazzoni P. In vitro study on the interaction of extracts and pure compounds from Valeriana officinalis roots with GABA, benzodiazepine and barbiturate receptors in rat brain. Fitoterapia 1993, 64:291-300.
34. Murphy K., Kubin Z.J., Shepherd J.N., Ettinger R.H. Valeriana officinalis root extracts have potent anxiolytic effects in laboratory rats. Phytomedicine 2010, 17:674-678.
35. Nestler E.J., Barrot M., DiLeone R., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
36. 1A receptors. Bioorg Med Chem 2010, 18:1925-1935.
37. Nutt D.J. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 2008, 69:4-7.
38. 1B receptors in the mediation of behavior in the forced swim test in mice. Neuropsychopharmacology 2001, 24:391-398.
39. 3H]GABA release. Neurochem Res 2004, 24:1373-1378.
40. Paparrigopoulos T., Psarros C., Bergiannaki J., Varsou E., Dafni U., Stefanis C. Melatonin response to clonidine administration in depression: indication of presynaptic alpha2-adrenoceptor dysfunction. J Affect Disord 2001, 65:307-313.
41. Picillo M., Rocco M., Barone P. Dopamine receptor agonists and depression in Parkinson's disease. Parkinsonism Relat Disord 2010, 15:S81-S84.
42. Porcelli S., Draggo A., Fabbri C., Serreti A. Mechanisms of antidepressant action: an integrated dopaminergic perspective. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(7):1532-1543.
43. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
44. Porsolt R.D., Lenegre A., McArthur R.A. Pharmacological models of depression. Animal models in psychopharmacology 1991, 137-160. Birkhauser Verlag, Basel. B. Olivier, J. Mos, J.L. Slangen (Eds.).
45. Ruhé H.G., Huyser J., Swinkels J.A., Schene A.H. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006, 67(12):1836-1855.
46. Sah S.P., Mathela C.S., Chopra K. Antidepressant effect of Valeriana wallichii patchouli alcohol chemotype in mice: behavioural and biochemical evidence. J Ethnopharmacol 2011, 135(1):197-200.
47. Sarris J., Kavanagh D.J., Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. J Psychiatr Res 2010, 44:32-41.
48. Sato A., Nakagawasai O., Tan-No K., Onogi H., Niijima F., Tadano T. Effect of non-selective dopaminergic receptor agonist on disrupted maternal behavior in olfactory bulbectomized mice. Behav Brain Res 2010, 210(2):251-256.
49. Silva A.L., Rech S.B., von Poser G.L. Quantitative determination of valepotriates from Valeriana native to south Brazil. Planta Med 2002, 68:570-572.
50. Stahl S.M. Essential psychopharmacology - neuroscientific basis and practical applications 2008, Cambridge University Press, New York. third ed.
51. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
52. Subhan F., Karim N., Gilani A.H., Sewell R.D.E. Terpenoid content of Valeriana wallichii extracts and antidepressant-like response profiles. Phytother Res 2010, 24:686-691.
53. Tufik S., Fujita K., Seabra M.L.V., Lobo L.L. Effects of a prolonged administration of valepotriates in rats on the mothers and their offspring. J Ethnopharmacol 1994, 41:39-44.
54. Viana A.F., Do Rego J.-C., Von Poser G.L., Ferraz A., Heckler A.P., Constantin J., et al. The antidepressant-like effect of Hypericum caprifoliatum Cham & Schlecht (Guttiferae) on forced swimming test results from an inhibition of neuronal monoamine uptake. Neuropharmacology 2005, 49:1042-1052.
55. Wang R., Xu Y., Wu H.L., Li Y.B., Li Y.H., Guo J.B., et al. The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors. Eur J Pharmacol 2008, 578:43-50.
56. Wang Y., Jin L., Yu S., Shi O., Gu Y., Kiyota H. Chemical constituents of plants from the genus Valeriana. Mini-Rev Org Chem 2010, 7:161-172.
57. Zanatta L.M., Nascimento F.C., Barros S.V.T., Silva G.R.R.S., Zugno A.I., Netto C.A., et al. In vivo and in vitro effect of imipramine and fluoxetine on Na+K+ATPase activity in synaptic plasma membranes from the cerebral cortex of rats. Braz J Med Biol Res 2001, 34:1265-1269.
58. Zhang H.T., Whisler L.R., Huang Y., Xiang Y., O'Donnell J.M. Postsynaptic α-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior. Neuropsychopharmacology 2009, 34:1067-1077.